EON

Agency Announces Potential Links Are Being Investigated

Washington- The Food and Drug Agency has announced that it is investigating and evaluating the possible links between suicide, mood swings and the use of Singulair, also known as montelukast.

The Merck and Company, Inc makes singular.

Some patient who have been prescribed Singular to treat exercise induced Asthma, allergic rhinitis and asthma have reports wide mood swings, unpleasant thoughts and thoughts of suicide. This has greatly alarmed those in the medical community and has drawn the attention of the FDA in the issue.

Merck and Company has been working closely with the FDA to make adjustments to the printed warnings that are given to consumers who receive the drug prescription. In the most recent changes warning for anxiousness, tremor, depression and possible suicidal thoughts have been added to the written included warnings.

The FDA is working with Merck to issue additional information to prescribers, and consumers as they discover additional data. At the current time the FDA does not have any plans to interrupt or stop the sales of Singular, only that they are continuing to investigate.

The FDA process is normally lengthy, and it may be up to nine months before the current investigation is completed. The FDA process of evaluation and review is a long and painstaking process that works to investigate all sides of the issue.